Metraipolis › archive › dc_db9447e7d05b
Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event… — Europe PMC PMID:42358981
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42358981
- DOI
- 10.3389/fimmu.2026.1840323
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T15:05:06.690Z
- SHA-256 of the archived text
791e9ab7451865240a5f2e529087a83979a3768228b0e00a05f306e401741612- Stable URL of this page
https://metraipolis.com/documento/dc_db9447e7d05b
How to cite
Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event… — Europe PMC PMID:42358981 — Europe PMC (en), https://europepmc.org/article/MED/42358981 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_db9447e7d05b (Metraipolis archive dc_db9447e7d05b, sha256 791e9ab7451865240a5f2e529087a83979a3768228b0e00a05f306e401741612)
BibTeX
@misc{dcdb9447e7d05b,
title = {Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event… — Europe PMC PMID:42358981},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42358981},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_db9447e7d05b; sha256 791e9ab7451865240a5f2e529087a83979a3768228b0e00a05f306e401741612},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42358981. Agents can read the archived copy with the MCP tool read_document.